Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations

Publication | Open Access

DOI Full Paper Access

146

Citations

References

2017

Year

Paolo A. Ascierto, Petri Bono, Shailender Bhatia, Ignacio Melero, Marta Nyakas, Inge Marie Svane, James Larkin, Carlos Gomez‐Roca, Dirk Schadendorf, R. Dummer,

Annals of Oncology